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Abstract
Simple questions are the most commonly used measures of antiretroviral treatment (ART) adherence in sub-
Saharan Africa (SSA), but rarely validated. We administered five adherence questions in a public-sector primary
care clinic in rural South Africa: 7-day recall of missed doses, 7-day recall of late doses, a six-level Likert item, a
30-day visual analogue scale of the proportion of doses missed, and recall of the time when an ART dose was last
missed. We estimated question sensitivity and specificity in detecting immunologic (or virologic) failure assessed
within 45 days of the adherence question date. Of 165 individuals, 7% had immunologic failure; 137 individuals
had viral loads with 9% failure detected. The Likert item performed best for immunologic failure with sensi-
tivity/specificity of 100%/5% (when defining nonadherence as self-reported adherence less than ‘‘excellent’’),
42%/55% (less than ‘‘very good’’), and 25%/95% (less than ‘‘good’’). The remaining questions had sensitivities
17%, even when the least strict cutoffs defined nonadherence. When we stratified the analysis by gender, age,
or education, question performance was not substantially better in any of the subsamples in comparison to the
total sample. Five commonly used adherence questions performed poorly in identifying patients with treatment
failure in a public-sector ART program in SSA. Valid adherence measurement instruments are urgently required
to identify patients needing treatment support and those most at risk of treatment failure. Available estimates of
ART adherence in SSA are mostly based on studies using adherence questions. It is thus unlikely that our
understanding of ART adherence in the region is correct.
Introduction
Adherence to antiretroviral treatment (ART) is acrucial determinant of ART outcomes, including sur-
vival.1–7 Nonadherence results in virologic and immunologic
failure, clinical deterioration, and the development of viral
resistance, complicating further treatment and increasing the
risk of transmission of resistant virus.2,4,8–10 Valid methods to
assess adherence are thus an essential component of ART
programs.11,12 Questions on ART adherence are readily ac-
cessible, inexpensive, and easily and quickly administered in
clinical settings.9,13 They are thus a feasiblemethod tomonitor
adherence in sub-Saharan Africa (SSA), where neither the
human resources to performmore time-consuming adherence
assessment (such as counting of antiretroviral pills or re-
viewing pharmaceutical records) nor the financial resources
to conduct more costly assessment (such as electronic moni-
toring or monitoring of blood ART concentrations) may be
available. In fact, in many of the public-sector ART programs
in SSA, where three quarters of the world’s four million
people receivingART live,14–16 questions on adherence are the
only measure routinely used to assess adherence.17
However, these questions are only useful if they perform
well in identifying nonadherent patients.10,18 But questions on
ART adherence have rarely been validated as instruments to
detect treatment failure in routine clinical settings in SSA’s
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public sector. The few studies that have been conducted found
unsatisfactory performance of ART adherence questions in
identifying patients who fail treatment. In 34 patients in
routine care in Uganda, 3-day recall of missed doses and a
visual analogue scale were weakly correlated with viral load
level 12 weeks after ART initiation.24 In 238 individuals in a
routine clinic in Cameroon, 1-month recall of missed doses
had a very low sensitivity in detecting patients with virologic
treatment failure.25 The 2006 WHO treatment guidelines for
resource-limited settings do not provide clear recommenda-
tions regarding adherence measurement.12 The scarcity of
validated ART adherence questions in SSA is all the more
surprising because our understanding of ART adherence in
the region is largely based on patient responses to adherence
questions,19 and interventions to increase adherence in rou-
tine care are commonly evaluated using adherence questions
as outcome measures.20–23
Some studies outside of SSA have demonstrated significant
associations between self-reported adherence and viral load13
and antiretroviral (ARV) plasma concentrations.26 However,
other studies found that self-reported adherence was only
weakly correlated with viral suppression and antiretroviral
drug concentrations.27,28 It remains unclear whether ques-
tions on ART adherence are adequate instruments to assess
adherence in routine clinical settings in SSA.15,16,29,30 We
validate for the first time the performance of five commonly
used ART adherence questions against a gold standard of
treatment failure in a public sector, decentralized ART pro-
gram in rural KwaZulu-Natal, South Africa.
Methods
Study setting
Patients were enrolled in KwaMsane clinic, the primary
care clinic managing the largest number of HIV patients
within a public-sector ART program in the Hlabsia subdistrict
of KwaZulu-Natal, South Africa.31 The target population of
the clinic lives in a rural town, or in the surrounding semi-
urban and rural areas. ART is initiated at the clinic, free of
charge, by a physician to all patients in the program with
WHO stage IV disease or CD4 cell count less than 200 cells/
mm3. Before ART initiation patients complete three treatment
literacy sessions.17 The ART regimen, a first-line standard
triple-drug regimen consisting of stavudine, lamivudine, and
either efavirenz or nevirapine, is monitored and dispensed by
nurses and counsellors at 2 weeks, 4 weeks, and at 4-week
intervals thereafter. CD4 cell count and HIV viral load (VL)
are routinely measured every 6 months. Approximately 6000
adult patients were initiated in the program between October
2004 and September 2008.32
Adherence questions
After written informed consent, trained research staff with
prior experience in HIV counseling and treatment adminis-
tered five questions on ART adherence in isiZulu to patients
attending the clinic. The five adherence questions comprising
7-day recall of missed doses, the number of doses missed by
more than 2 hours in the past week, a Likert item with six
levels of adherence over the past month, a 30-day visual an-
alogue scale (VAS) of the proportion of doses missed, and a
multiple-choice question with seven responses eliciting the
time of the most recently missed dose within discrete time
intervals (Fig. 1). Except for the VAS, whichwas completed by
the patient after receiving instructions, self-reported adher-
ence questions were completed by the research staff. In ad-
dition to the adherence questions, the participants answered
questions on demographic, socioeconomic, and behavioral
factors, as well as on health status and health care seeking.
Clinical data, CD4 counts, and VL data were extracted from
the clinic files of each enrolled patient.
Samples
Patients who had received ART for at least 2 weeks, were
not pregnant, and were not planning to stop ART in the next 6
months were enrolled between November 2007 and February
2008. Baseline analyses of the performance of adherence
questions included all patients with a CD4 count (n¼ 165) or a
viral load (n¼ 137) within 45 days of the date on which the
adherence questions were administered.
Outcome definitions
Both immunologic and virologic failure definitions were
based on WHO criteria for treatment failure,33 as relevant for
this study. Immunologic treatment failure was defined as less
than 100 cells/mm3 after 6 months of ART. Virologic treat-
ment failure was defined as a VL greater than 10,000 copies
per milliliter after being on ART for over 6 months, or greater
than 400 copies per milliliter after a previously undetectable
viral load.
We started evaluating the performance of the different
adherence questions, assuming that patients will fail treat-
ment if they do not adhere near-perfectly,34 i.e., considering
any adherence level greater than 95% (for the 7-day recall of
missed doses, the 7-day recall of late doses, and the VAS),
any adherence level less than ‘‘excellent’’ (for the six-level
Likert item), and any adherence level less than ‘‘never’’ (for
the question about the time of the last missed dose) as
‘‘nonadherent.’’ We then assessed whether the adherence
questions performed differently as diagnostic tests predicting
treatment failure at alternative non-adherence cut-offs.35 For
the six-level Likert item on adherence, we used the additional
nonadherence cutoffs less than ‘‘very good’’ and less than
‘‘good’’; for the multiple-choice question on the time of the
last missed dose, we used the additional cutoffs of any time
more recent than ‘‘1 month’’ and more recent than ‘‘2 weeks.’’
For the remaining three questions, we used the additional
cutoffs less than 85% and less than 75% of prescribed doses
taken.
Statistical analysis
We used immunologic or virologic treatment failure as
gold standard to evaluate the questions of nonadherence.
Sensitivity, specificity, and corresponding 95% confidence
intervals for varying cutoffs are reported for each self-
reported adherence question. To assess the robustness of
results to changes in the time of assessment of treatment
failure relative to the date of the adherence questions, we
also computed sensitivity and specificity for the samples of
patients with biologic measures of treatment outcomes more
than 3 months (resulting in samples of n¼ 165 for CD4 count
and n¼ 139 for VL) or more than 6 months (n¼ 124 for CD4
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count and n¼ 111 for VL) after the interview date. All
analyses were conducted using STATA v11.0 (College
Station, TX).
Results
Of individuals in the CD4 count sample, 12 (7%) had im-
munologic failure, while 13 (9%) in the VL sample had viro-
logic failure. Within the virologic failure group, 44% percent
had a VL greater than 10,000 copies/ml after 6 months of
therapy. Patient characteristics are described in Table 1.
The six-level Likert item performed best in detecting im-
munologic failure, with sensitivity/specificity of 100%/5%,
42%/55%, and 25%/95% for immunologic failure when in-
dividuals reported less than ‘‘excellent,’’ less than ‘‘very
good,’’ less than ‘‘good’’ adherence, respectively. The re-
maining four questions had sensitivities of 17% or less, even
when the least strict cutoffs defined nonadherence. For viro-
logic failure, the Likert item again performed best with sen-
sitivity/specificity of 92%/3%, 23%/55%, and 8%/95% for
immunologic failure when individuals reported less than
‘‘excellent,’’ less than ‘‘very good,’’ or less than ‘‘good’’ ad-
herence, respectively. The remaining four questions had
sensitivities 8% or less, even when the least strict cutoffs de-
fined nonadherence (Table 2). Note that the confidence in-
tervals around the sensitivity estimates are substantially
wider than those around the specificity estimates, because the
sample sizes for sensitivity estimation were substantially
smaller than those for specificity estimation as most individ-
uals in our sample had not failed treatment.
Question performance remained essentially unchanged
when assessed against virologic failure or against combined
FIG. 1. Adherence questionnaire.
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immunologic or virologic failure. Neither sensitivity nor
specificity of the questions improved significantly when CD4
counts (or VLs) more than 3 months or more than 6 months
after the date of the adherence question were used as gold
standard in the analysis. Similarly, when we identified non-
adherent individuals through an initial screening test (using
the highly sensitive six-level Likert item) and then confirmed
the diagnosis of nonadherence with a second adherence
question (using one of the four highly specific questions), test
performance did not improve significantly in comparison to
the individual questions alone. None of the other possible
combinations of adherence questions, including combinations
of more than two questions, had better performance charac-
teristics than the best-performing individual question in-
cluded in the combination.
We further tested whether the performance of the adher-
ence questions was better in particular subsamples than in the
total sample by stratifying the analysis by sex, age (below 35
versus 35 or older), and education level (below secondary
education versus secondary education or higher). While the
performance of the questions varied across the strata, it did
not improve significantly in any of the strata in comparison to
the performance in the total sample. For instance, in the val-
idation against CD4 count the performance characteristics of
Table 1. Sample Characteristics
CD4 count sample
N¼ 165
VL sample
N¼ 137
Female (%) 76 81
Age (median [IQR]) 38 (33–44) 38 (33–44)
Level of education
None (%) 10 9
Primary school (%) 30 28
Secondary school
or higher (%)
60 63
Travel time to clinic
in minutes [median (IQR)]
30 (15–40) 30 (20–40)
Disability grant for HIV (%) 45 47
Disclosure of HIV status
to family or friend (%)
100 100
Time on ARV in months
[median (IQR)]
14 (9–25) 14 (9–25)
Treatment failure
Immunologic failure (%) 7 —
Virologic failure (%) — 9
IQR, interquartile range.
Table 2. Sensitivity and Specificity of Adherence Questions in Detecting Treatment Failure
Question item
Nonadherence
cutoff
Number reporting
nonadherence Sensitivity
95%
CI Specificity
95%
CI
CD4 count sample (n¼ 165)
7-day recall of missed doses <95% 6 0 0–26 96 92–99
<85% 1 0 0–26 99 96–100
<75% 1 0 0–26 99 96–100
7-day recall of missed doses 2 h <95% 5 0 0–26 97 93–99
<85% 1 0 0–26 99 96–100
<75% 0 0 0–2 100 74–100
Six-level Likert item <Excellent 157 100 74–100 5 2–9
<Very good 73 42 15–72 55 47–63
<Good 11 25 5–57 95 90–98
30-day VAS <95% 7 0 0–26 95 91–98
<85% 0 0 0–2 100 74–100
<75% 0 0 0–2 100 74–100
Last missed dose <Never 27 17 2–48 84 77–89
<1 month 10 0 0–26 93 88–97
<2 weeks 1 0 0–26 99 96–100
VL sample (n¼ 137)
7-day recall of missed doses <95% 4 0 0–25 97 92–99
<85% 0 0 0–3 100 75–100
<75% 0 0 0–3 100 75–100
7-day recall of missed doses 2 h <95% 4 0 0–25 97 92–99
<85% 1 0 0–25 99 96–100
<75% 0 0 0–3 100 75–100
Six-level Likert item <Excellent 131 92 64–100 3 1–8
<Very good 59 23 5–54 55 45–64
<Good 7 8 0–36 95 90–98
30-day VAS <95% 3 0 0–25 98 93–100
<85% 1 0 0–25 99 96–100
<75% 0 0 0–3 100 75–100
Last missed dose <Never 22 8 0–36 83 75–89
<1 month 6 0 0–25 95 90–98
<2 weeks 1 0 0–25 99 96–100
CI, confidence interval; VAS, visual analogue scale; VL, viral load.
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the best-performing measure (the six-level Likert item with a
nonadherence cutoff of less than ‘‘very good’’) differed
between the stratum with higher education level (50% sensi-
tivity (95% confidence interval [CI] 16–84%) and 54% speci-
ficity (95% CI 45–64%) and the total population (42%
sensitivity [95% CI 15–72%] and 55% specificity (95% CI
47–63%). However, these differences were neither substantial
nor statistically significant.
Discussion
Questions on ART adherence are the most widely used
instruments to measure adherence in treatment programs in
SSA. We find that five questions commonly used in clinical
research and practice to assess adherence, including the one
currently used in the public sector in South Africa, perform
poorly in detecting patients who fail treatment. Estimates of
ART adherence in SSA are mostly based on responses to ad-
herence questions.19 Our findings thus suggest that ART ad-
herence in the region has been overestimated.
Reasons for ART failure other than nonadherence are
generally rare in our context.36 However, it is theoretically
possible that a proportion of patients failed treatment despite
current high levels of adherence, resulting in an underesti-
mate of sensitivity. First, primary viral resistance could, of
course, have resulted in treatment failure in perfectly adher-
ing patients.37–39 But, according both to results frommodeling
studies40 and local empirical evidence41,42 primary resistance
was very rare in South Africa during the time of this study.
Hence, we would not expect primary resistance to have
affected our results.
Second, concomitant treatment for tuberculosis (TB) can
interact with some antiretroviral drugs, leading to subthera-
peutic ART concentrations.43,44 As Boulle et al.45 showed,
however, TB treatment only affects the probability of virologic
failure in patients receiving the standard South African triple-
drug regimen with nevirapine, which is only recommended
for ‘‘pregnant women or women of child-bearing age, not on
reliable contraception,’’17 while it does not affect the regimen
with efavirenz. The South African treatment guidelines thus
specifically recommend the regimen containing efavirenz for
all patients with TB coinfection.17 In all samples in this study,
less than one quarter of the patients received a regimen with
nevirapine, and less than one fifth of this group was simul-
taneously treated for TB. It is thus unlikely that TB treatment
was responsible for a significant proportion of treatment
failures in this study.
Third, HIV-related conditions may reduce ART blood-
levels, leading to treatment failure despite perfect adherence.
For example, HIV-associated enteropathy can cause vomiting,
diarrhea, or malabsorption, reducing ART blood levels and
manifesting as treatment failure.46,47 Finally, it has been sug-
gested that some of the medicines given by traditional healers
in KwaZulu-Natal can change the pharmacokinetics of ART.48
However, all patients failing treatment according to either
CD4 count or VL reported they did not receive care from the
two types of traditional healers—sangoma and inyanga—who
most commonly prescribe traditional medicines in this area.49
Overall, it is thus unlikely that reasons for treatment failure
other than nonadherence have biased our findings.
Another potential source of bias in our baseline results are
the lag times between adherence and immunologic or viro-
logic response.50 But our results remained essentially un-
changed when we used only CD4 count or VL in the analyses
that were measured 3 or 6 months after the date of the ad-
herence assessment, demonstrating that lags are unlikely to
have affected our findings.
A general limitation of most adherence questions is that
they provide little information on the longitudinal pattern of
adherence. For example, patients answering to the multiple-
choice question that they missed the last dose ‘‘yesterday’’
could theoretically have missed one dose the day before but
never missed a dose previously or they could have consecu-
tively missed doses over several past days including the day
before. Similarly, the VAS does not differentiate between all
the different possible time patterns of nonadherence that im-
ply any given proportion of doses missed over the past 30
days. Because the pattern by which patients fail to take their
medication can have significant impact on their treatment
outcomes and the development of resistance,37,39,51 the in-
ability of self-reported adherence to capture adherence time
patterns limits their utility in detecting patients with adher-
ence problems. Once a patient has been identified as non-
adherent, a more extensive dialogue with the patient may be
necessary to identify the patterns and causes of non-adherence,
in order to determine appropriate adherence support inter-
vention.14
The location where an adherence question is asked may be
an important determinant of the validity of the answer. For
instance, when answering an adherence question in a public-
sector clinic where ART are free of charge a patient may be
more likely to fear negative consequences of reporting non-
adherence (such as treatment discontinuation) than when an-
swering the same question in a private-sector clinic where she
pays for her ART. In this study in a public-sector clinic, we
emphasized in the informed consent procedure that answers
to the questions in the study questionnaire would be com-
pletely confidential and that reporting nonadherence would
not lead to any negative consequences, in order to minimize
intentional adherence misreporting. Nevertheless, future
studies should examinewhether the adherence questions used
in this study perform better in identifying nonadherent pa-
tients when asked outside the setting of a public-sector clinic.
Adherence is a crucial determinant of ART success. Note,
however, that different ART regimens may require different
minimum levels of adherence to ensure successful treatment.
A minimum adherence threshold of 95% of all prescribed
doses taken was established initially as necessary for patients
receiving an unboosted protease inhibitor and two nucleoside
reverse transcriptase inhibitors to ensure the highest proba-
bility of viral suppression.7 More recent reports indicate that
moremoderate levels of adherencemay be sufficient to ensure
viral suppression for the majority of patients receiving boos-
ted protease inhibitor-based regimens or nonnucleoside re-
verse transcriptase inhibitor-based regimens.52,53 Since most
patients in public-sector ART programs in South Africa, such
as the patients in our sample, receive non-nucleoside reverse
transcriptase inhibitors (either efavirenz or nevirapine), it is
possible that adherence levels below 95% are sufficient for
treatment success in South Africa. Future studies need to es-
tablish the precise minimum adherence thresholds for the
routine first-line ART regimens in this setting.
Independent of the precise minimum adherence required
for treatment success, the ability to simply and validly
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measure ART adherence is crucial for the long-term success of
the recent initiatives to bring ART to scale in SSA. It is nec-
essary to detect patients who are failing treatment and require
additional support, in order to prevent the development of
resistance. In the absence of resistance testing, it is further
important to identify those who despite ongoing and re-
inforced adherence still fail treatment and thus require regi-
men change.54 Our study shows that simple questions, which
are commonly used in routine care, are insufficient for this
purpose. It will be important to understand the reasons for the
poor performance of these adherence questions in the public-
sector treatment programs in South Africa, which could
include social desirability bias, imperfect recall, or misinter-
pretations of the purpose of the questions.1,2,14,55–57 It will
further be important to reassess our knowledge on ART ad-
herence in SSA. Available estimates of ART adherence in the
region aremostly based on studies using adherence questions.
It is thus unlikely that our understanding of ART adherence in
the region is correct.
Instruments that can be used in ART programs in SSA to
identify individuals adhering imperfectly are urgently needed
in order to provide additional support to prevent treatment
failure and resistance development. Ideally such instruments
would be neither costly nor time consuming. However, if
instruments that are inexpensive and quick to administer, such
as patient adherence questions or health worker estimates of
adherence,58 do not lead to valid adherence estimates, policy
makers need to consider whether more resource-intensive
measures, such as pill counts or electronic monitoring, should
be routinely employed in public-sector treatment programs
in SSA.
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